Physician profile

Sherry Narang

Ophthalmology · Columbia, MD

NPI 1861659740

$386.97

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$99.21

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Shire North American Group INC $90.08 2019
Allergan, INC. $71.79 2019-2020
Novartis Pharmaceuticals Corporation $65.24 2019-2023
Carl Zeiss Meditec Ag $38.80 2020
Dompe US, INC. $33.39 2024 Oxervate
Glaukos Corporation $27.08 2024 Idose
Sun Pharmaceutical Industries INC. $24.87 2020
Bausch & Lomb, A Division of Bausch Health US, LLC $18.48 2021
Carl Zeiss Meditec, INC. $17.24 2020

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Sherry Narang

$386.97

in general payments reported 2019-2025

Years
2019-2024
Top company
Shire North American Group INC

https://glasscript.com/doctor/786455/sherry-narang

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.